Patent intelligence · US
US 9944929
UNA single stranded oligomers for therapeutics
UNA single stranded oligomers for therapeutics
Patent details — US 9944929
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 17, 2018
- Expiration
- Apr 12, 2038
- Applicant
- ARCTURUS THERAPEUTICS, INC.
- Claims
- 9
- CPC classes
- A61P, A61P35/00
Quick answer
US 9944929 (UNA single stranded oligomers for therapeutics) is held by ARCTURUS THERAPEUTICS, INC.. Status: granted. Granted Apr 17, 2018. Expires Apr 12, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARCTURUS THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61P, A61P35/00
More from ARCTURUS THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12398379
Compositions and methods for treating ornithine transcarbamylase deficiency
granted -
US 12390524
Compositions and methods for inducing immune responses
granted -
US 12351834
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
granted -
US 12290567
Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates
granted -
US 12286395
Method of synthesis of an ionizable cationic lipid
granted -
US 12220485
Method of making lipid-encapsulated RNA nanoparticles
granted -
US 12220455
Coronavirus vaccine compositions and methods
granted -
US 12178921
Method of lyophilizing lipid nanoparticles
granted
Frequently asked questions
What is US patent 9944929?
US 9944929 (UNA single stranded oligomers for therapeutics) is held by ARCTURUS THERAPEUTICS, INC.. Status: granted. Granted Apr 17, 2018. Expires Apr 12, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9944929?
ARCTURUS THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 55 pharmaceutical patents for this assignee.
When does US 9944929 expire?
Our index shows an expiration date of Apr 12, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.